



vTv Therapeutics to Participate in Fireside Chat at Piper Jaffray 27th Annual Healthcare Conference

November 24, 2015

HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 24, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will participate in an analyst-led fireside chat at 4:00 p.m. EST on Wednesday, December 2 at the Piper Jaffray 27th Annual Healthcare Conference.

A live webcast can be accessed on the [News & Events](#) section of the website. The webcast will be archived for 30 days following the presentation on the company website at www.vtvtherapeutics.com.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20151124005098/en/>

Source: vTv Therapeutics Inc.

vTv Therapeutics Inc.

Investors

The Trout Group

Josh Barer, 646-378-2948

jbarer@troutgroup.com

or

Media

BMC Communications

Brad Miles, 646-513-3125

bmiles@bmccommunications.com